Inhalable tiotropium and container therefor

• US 20070104655A1
• Filed: 06/08/2006
• Published: 05/10/2007
• Est. Priority Date: 12/03/2003
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Nilsson, Thomas, Zierenberg, Bernd, Memmesheimer, Holger, Myrman, Mattias, Lunkenheimer, Christine, Niemi, Alf, Calander, Sven
• Application Number:
  US11/448,765
• Publication Number:
  US 20070104655A1
• Time in Patent Office: Days
• US Class Current: 424/46
• CPC Class Codes: A61K 31/439 the ring forming part of a bridged ring system, e.g. quinuclidine 8-azabicyclo [3.2.1] octanes A61K31/46
• CPC Class Codes: A61K 9/0075 for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/08 Bronchodilators

Abstract

A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same.

Claims

1. A medical product comprising a dry powder medicament dose loaded into a container for use in a dry powder inhaler, wherein the dry powder medicament dose comprises a fine particle dose of tiotropium and at least one dry excipient present in the form of finely divided particles;

and wherein the container comprises a dry, high barrier seal, and the dry powder medicament dose in the container is adapted for either volumetric or electric field dose forming methods.

2. The medical product according to claim 1, wherein the at least one dry excipient has a mass median aerodynamic diameter of 10 μ

m or less.

3. The medical product according to claim 2, wherein the at least one dry excipient is selected from the group consisting of glucose, arabinose, lactose, lactose monohydrate, lactose unhydrous, saccharose, maltose, dextrane, sorbitol, mannitol, xylitol, sodium chloride, calcium carbonate, and mixtures thereof.

4. The medical product according to claim 1, wherein the at least one dry excipient is selected from the group consisting of glucose, arabinose, lactose, lactose monohydrate, lactose unhydrous, saccharose, maltose, dextrane, sorbitol, mannitol, xylitol, sodium chloride, calcium carbonate, and mixtures thereof.

5. The medical product according to claim 2, comprising at least one additional dry excipient having a mass median aerodynamic diameter of 25 μ

m or more.

6. The medical product according to claim 1, wherein the at least one dry excipient is selected from the group consisting of polylactides, polysaccharides, polymers, salts, and mixtures thereof.

7. The medical product according to claim 1, wherein the container further comprises a desiccant.

8. The medical product according to claim 5, wherein the at least one additional dry excipient is selected from the group consisting of polylactides, polysaccharides, polymers, salts, and mixtures thereof.

9. The medical product according to claim 1, wherein the dry, high barrier seal comprises aluminum foil, and the at least one dry excipient is selected from the group consisting of lactose, lactose anhydrous, lactose monohydrate, and mixtures thereof.

10. The medical product according to claim 9, wherein the at least one dry excipient has a mass median aerodynamic diameter of 10 μ

m or less and further comprising at least one additional dry excipient having a mass median aerodynamic diameter of 25 μ

m or more.

11. The medical product according to claim 1, wherein the dry, high barrier seal is formed of at least one material selected from the group consisting of metal, thermoplastics, glass, silicon, silicon oxides, and mixtures thereof.

12. The medical product according to claim 11, wherein the dry, high barrier seal comprises aluminum foil.

13. The medical product according to claim 1, wherein the at least one dry excipient is selected from the group consisting of lactose, lactose anhydrous, lactose monohydrate, and mixtures thereof.

14. The medical product according to claim 1, wherein the dry, high barrier seal comprises a formed aluminum foil, a flat aluminum foil, or both.

15. The medical product according to claim 14, wherein the dry, high barrier seal further comprises a polymer layer laminated to the formed aluminum foil, the flat aluminum foil, or both.

16. A device comprising a dry powder inhaler and the medical product according to claim 1.

17. The device according to claim 16, wherein the device comprises a desiccant.

18. A device comprising a dry powder inhaler and the medical product according to claim 1, wherein the container of the medical product is contained within the dry powder inhaler.

19. The device according to claim 17, wherein the device comprises a desiccant.

20. A kit comprising a dry powder inhaler and the medical product according to claim 1, wherein the container is separate from the dry powder inhaler and the container is adapted for insertion into the dry powder inhaler.

21. The kit according to claim 18, wherein the device comprises a desiccant.

22. A device comprising a dry powder inhaler and the medical product according to claim 1, wherein the container is separate from the dry powder inhaler and the container comprises a first part adapted for insertion into a dry powder inhaler and a second part enclosing the first part in a moisture-bight package.

23. The medical product according to claim 1, adapted such that the fine particle dose of the medicament delivered from a dry powder inhaler represents more than 20% of the pre-metered dose and 40% of the delivered dose.

24. A method of treating asthma in an individual, comprising delivering to an individual in need thereof a fine particle dose of tiotropium through a delivery device comprising the medical product according to claim 1, such that tiotropium is delivered to the individual in an amount sufficient to treat the asthma in the individual.

25. A method of treating an obstructive pulmonary disease in an individual, comprising delivering to an individual in need thereof a fine particle dose of tiotropium through a delivery device comprising the medical product according to claim 1, such that tiotropium is delivered to the individual in an amount sufficient to treat the obstructive pulmonary disease in the individual.

26. The medical product according to claim 1, wherein the dry powder medicament further comprises at least one additional active pharmaceutical ingredient.

27. The medical product according to claim 26, wherein the high barrier container includes a desiccant.

28. The medical product according to claim 26, wherein the at least one additional active pharmaceutical ingredient is selected from the group consisting of inhalable steroids, nicotinamide derivatives, beta-agonists, beta-mimetics, anti-histamines, adenosine A2A receptors, PDE4 inhibitors, dopamine D2 receptor agonists, and mixtures thereof.

29. The medical product according to claim 26, wherein the at least one additional pharmaceutical ingredient is selected from the group consisting of budesonid, fluticasone, rofleponide, mometasone, ciclesonide epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifene, emedastine, dimetindene, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine, meclozine, formoterol, salmeterol, salbutamol, terbutalinsulphate, 3′

,5′

-cyclic nucleotide phosphodiesterases, 3′

,5′

-cyclic nucleotide phosphodiesterases derivatives, ribofuranosylvanamide, ribofuranosylvanamide derivatives, and mixtures thereof.

30. The medical product according to claim 26, wherein the at least one dry excipient has a mass median aerodynamic diameter of 10 μ

m or less.

31. The medical product according to claim 30, wherein the at least one dry excipient is selected from the group consisting of glucose, arabinose, lactose, lactose monohydrate, lactose unhydrous, saccharose, maltose, dextrane, sorbitol, mannitol, xylitol, sodium chloride, calcium carbonate, and mixtures thereof.

32. The medical product according to claim 26, wherein the at least one dry excipient is selected from a group consisting of glucose, arabinose, lactose, lactose monohydrate, lactose unhydrous, saccharose, maltose, dextrane, sorbitol, mannitol, xylitol, sodium chloride, calcium carbonate, and mixtures thereof.

33. The medical product according to claim 26, wherein the at least one dry excipient is selected from the group consisting of polylactides, polysaccharides, polymers, salts, and mixtures thereof.

34. The medical product according to claim 26, further comprising at least one additional dry excipient having a mass median aerodynamic diameter of 25 μ

m or more.

35. The medical product according to claim 34, wherein the at least one additional dry excipient is selected from the group consisting of polylactides, polysaccharides, polymers, salts, and mixtures thereof.

36. The medical product according to claim 26, wherein the dry, high barrier seal is formed of a material selected from the group consisting of metal, thermoplastics, glass, silicon, silicon oxides, and mixtures thereof.

37. The medical product according to claim 36, wherein the dry, high barrier seal comprises metal, which is aluminum foil.

38. The medical product according to claim 26, wherein the at least one dry excipient is selected from the group consisting of lactose, lactose anhydrous, lactose monohydrate, and mixtures thereof.

39. The medical product according to claim 26, wherein the dry, high barrier seal comprises a formed aluminum foil, a flat aluminum foil, or both.

40. The medical product according to claim 39, wherein the dry, high barrier seal further comprises a polymer layer laminated to the formed aluminum foil, the flat aluminum foil, or both.

41. A device comprising a dry powder inhaler and the medical product according to claim 26.

42. A device comprising a dry powder inhaler and the medical product according to claim 26, wherein the container of the medical product is contained within the dry powder inhaler.

43. A kit comprising a dry powder inhaler and the medical product according to claim 26, wherein the container is separate from the dry powder inhaler and the container is adapted for insertion into the dry powder inhaler.

44. A kit comprising a dry powder inhaler and the medical product according to claim 26, wherein the container is separate from the dry powder inhaler and the container comprises a first part adapted for insertion into a dry powder inhaler and a second part enclosing the first part in a moisture-tight package.

45. The medical product according to claim 26, adapted such that the fine particle dose of the medicament delivered from a dry powder inhaler represents more than 20% of the pre-metered dose and 40% of the delivered dose.

46. A method of treating asthma in an individual, comprising delivering to an individual in need thereof a fine particle dose of tiotropium through a delivery device comprising the medical product according to claim 26, such that tiotropium is delivered to the individual in an amount sufficient to treat the asthma in the individual.

47. A method of treating an obstructive pulmonary disease in an individual, comprising delivering to an individual in need thereof a fine particle dose of tiotropium through a delivery device comprising the medical product according to claim 26 such that tiotropium is delivered to the individual in an amount sufficient to treat the obstructive pulmonary disease in the individual.

48. The medical product according to claim 26, wherein the at least one additional active pharmaceutical ingredient replaces the excipient, partly or completely.